フィルグラスチムバイオシミラーの世界市場レポート 2024

フィルグラスチムバイオシミラーの市場規模は、今後数年間で急速に成長すると予想されています。 2028年には10.7%の年間複合成長率（CAGR）で16億6,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、人口の高齢化とヘルスケアアクセスの増加に起因すると考えられます。この期間の主な動向としては、効果的で革新的なバイオシミラーの創出のための研究開発（R&D）活動への多額の投資、収益向上を目的とした好中球減少症治療を対象としたバイオシミラーの生産、成長戦略としての合併・買収（M&A）への集中の強化などが挙げられます。

フィルグラスチムバイオシミラー市場の予想される成長は、好中球減少症の有病率の増加によって推進されています。感染防御に不可欠な白血球である好中球の不足を特徴とする好中球減少症は、フィルグラスチムバイオシミラーで対処できます。これらのバイオシミラーは骨髄における好中球の産生を刺激し、好中球数を増加させ、感染症に対する抵抗力を高めます。たとえば、国立バイオテクノロジー情報センターから提供された2022年 8月のデータでは、好中球減少症の有病率がメキシコ系アメリカ人で0.38%、白人で0.79%、黒人の参加者で4.5%であることが明らかになりました。したがって、好中球減少症の有病率の上昇は、フィルグラスチムバイオシミラー市場の成長を推進する重要な要因です。

バイオシミラー開発に特化した政府の取り組みは、今後数年間でフィルグラスチムバイオシミラー市場の拡大に貢献する態勢が整っています。世界各国政府は、その費用対効果の高さからバイオシミラー開発を重視しています。米国食品医薬品局（FDA）のバイオシミラー行動計画やオーストラリアのバイオシミラー啓発イニシアチブへの取り組みなどの取り組みは、治療選択肢の増加とバイオシミラー教育の促進に戦略的に焦点を当てていることを強調しています。オーストラリア政府からジェネリック・バイオシミラー医薬品協会への500万米ドルの助成金を含むこの支援は、バイオシミラー医薬品の調剤、処方、使用に関する認識と活動を強化します。したがって、政府の取り組みは、フィルグラスチムバイオシミラー市場の成長促進において極めて重要な役割を果たしています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の市場促進要因と抑制要因
  • 市場促進要因
  • 市場抑制要因
• 世界の市場規模実績と成長、2018年～2023年
• 世界の市場規模予測と成長、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界のフィルグラスチムバイオシミラー市場、製造タイプ別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 社内製造
• 受託製造組織
• 世界のフィルグラスチムバイオシミラー市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 腫瘍学
• 慢性疾患および自己免疫疾患
• 血液疾患
• 成長ホルモン欠乏症
• 感染症
• その他の用途
• 世界のフィルグラスチムバイオシミラー市場、流通チャネル別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 地域および国の分析

• 世界のフィルグラスチムバイオシミラー市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
• 世界のフィルグラスチムバイオシミラー市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• フィルグラスチムバイオシミラー市場の競合情勢
• フィルグラスチムバイオシミラー市場の企業プロファイル
  • Teva Pharmaceutical Industries Ltd
  • Novartis International AG
  • Biocon Limited
  • Intas Biopharmaceuticals
  • Dr. Reddy's Laboratories

第31章 その他の大手および革新的な企業

• Pfizer
• Cadila Healthcare Ltd
• Abbott Laboratories
• Reliance Life Science Pvt. Ltd
• Gennova Biopharmaceuticals（Emcure）
• Sandoz Pty Ltd
• Apotex Pty Ltd
• Mylan
• Kyowa Kirin Co. Ltd
• Lupin Limited
• Biocon Biologics
• Coherus Biosciences Inc.
• North China Pharmaceutical Corporation
• Tonghua Dongbaoare
• Beijing SL Pharmaceutical

第32章 競合ベンチマーキング

第33章 競合ダッシュボード

第34章 主要な合併と買収

第35章 将来の見通しと可能性の分析

第36章 付録

Filgrastim biosimilars are biosimilars designed to address bone marrow damage caused by extremely high radiation doses, similar to their use in cancer patients. These biosimilars work by stimulating the production of white blood cells, reducing the susceptibility of patients to infections.

There are two primary manufacturing types for the filgrastim biosimilar market in-house manufacturing and contract manufacturing organization (CMO). A contract manufacturing organization, also known as a contract development and manufacturing organization, is a company that offers comprehensive services to other pharmaceutical firms on a contractual basis, covering activities from drug discovery to drug production. The diverse applications of filgrastim biosimilars include oncology, chronic and autoimmune diseases, blood disorders, growth hormone deficiency, infectious diseases, and others. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The filgrastim biosimilar markets market research report is one of a series of new reports from The Business Research Company that provides filgrastim biosimilar markets market statistics, including filgrastim biosimilar markets industry global market size, regional shares, competitors with a filgrastim biosimilar markets market share, detailed filgrastim biosimilar markets market segments, market trends and opportunities, and any further data you may need to thrive in the filgrastim biosimilar markets industry. This filgrastim biosimilar markets market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The filgrastim biosimilars market size has grown strongly in recent years. It will grow from $1.02 billion in 2023 to $1.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth witnessed in the historical period can be ascribed to the expansion of emerging markets, the rise in patent expiration, government initiatives, augmented healthcare expenditure, cost-effectiveness of biosimilars, a robust drug pipeline, and an upswing in biopharmaceutical research and development expenditure.

The filgrastim biosimilars market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth in the forecast period can be attributed to the aging population and an increase in healthcare access. Key trends during this period include substantial investments in research and development (R&D) activities for the creation of effective and innovative biosimilars, the production of biosimilars targeting neutropenia treatment to enhance revenues, and an intensified focus on mergers and acquisitions (M&A) as growth strategies.

The anticipated growth of the filgrastim biosimilar market is driven by the increasing prevalence of neutropenia. Neutropenia, a condition characterized by insufficient neutrophils, crucial white blood cells in infection defense, can be addressed with filgrastim biosimilars. These biosimilars stimulate neutrophil production in the bone marrow, elevating neutrophil counts and aiding in infection resistance. For example, data from August 2022, sourced from the National Center for Biotechnology Information, revealed neutropenia prevalence rates of 0.38% among Mexican-Americans, 0.79% among whites, and 4.5% among black participants. Consequently, the rising prevalence of neutropenia is a significant factor propelling the filgrastim biosimilar market's growth.

Government initiatives dedicated to biosimilar development are poised to contribute to the filgrastim biosimilar market's expansion in the coming years. Global governments are emphasizing biosimilar development due to its cost-effectiveness. Initiatives such as the US Food and Drug Administration's (FDA) Biosimilar Action Plan and Australia's commitment to the Biosimilar Awareness Initiative highlight a strategic focus on increasing treatment options and promoting biosimilar education. This support, including a $5 million grant from the Australian government to the Generic and Biosimilar Medicines Association, enhances awareness and activities related to biosimilar medicines' dispensing, prescription, and use. Thus, government initiatives play a pivotal role in fostering the growth of the filgrastim biosimilar market.

Prominent firms in the filgrastim biosimilar market are at the forefront of creating innovative products utilizing advanced technologies, such as recombinant DNA technology, to manufacture biosimilars. Recombinant DNA technology involves the creation of hybrid DNA by integrating a foreign sequence into an organism's DNA. For instance, in May 2023, Amneal Pharmaceuticals, a US-based pharmaceutical company, introduced FYLNETRA (pegfilgrastim-pbbk), a biosimilar to Amgen's NEULASTA in the United States. It is indicated for treating and preventing febrile neutropenia, facilitating neutrophil expansion, maturation, and enhanced viability and efficiency. FYLNETRA's launch aims to provide affordable medicines, expanding access for patients, providers, and payors.

Leading companies in the filgrastim biosimilar market continue to innovate with products such as Releuko (filgrastim-ayow) to better address patient needs. Releuko (filgrastim-ayow), referencing Neupogen (filgrastim), is designed for treating and preventing febrile neutropenia in cancer patients undergoing chemotherapy. In November 2022, Amneal Pharmaceuticals and Kashiv Biosciences, both US-based companies, jointly launched Releuko (filgrastim-ayow) in the US market. Contraindications include patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors. This approval marks Amneal's debut in the biosimilar realm, with more decisions anticipated by year-end.

In March 2022, Biocon Biologics, an India-based fully integrated biopharmaceutical company, completed the acquisition of Viatris Inc. for $3.3 billion, creating a robust, globally integrated biosimilars enterprise. This strategic collaboration leverages the strengths and complementary expertise of both entities, positioning Biocon Biologics for a decade of value generation for stakeholders. Viatris Inc., a US-based pharmaceutical company, has developed a biosimilar of pegfilgrastim.

Major companies operating in the filgrastim biosimilars market report are Teva Pharmaceutical Industries Ltd., Novartis International AG, Biocon Limited, Intas Biopharmaceuticals, Dr. Reddy's Laboratories, Pfizer, Cadila Healthcare Ltd., Abbott Laboratories, Reliance Life Science Pvt. Ltd., Gennova Biopharmaceuticals (Emcure), Sandoz Pty Ltd., Apotex Pty Ltd., Mylan, Kyowa Kirin Co. Ltd., Lupin Limited, Biocon Biologics, Coherus Biosciences Inc., North China Pharmaceutical Corporation, Tonghua Dongbaoare, Beijing SL Pharmaceutical, Mochida Pharmaceutical, Fuji Pharma, Amgen (Europe) GmbH, Napp Pharmaceuticals, Adello Biologics, Apobiologix (Apotex), Hospira, Tanvex BioPharma, Eurofarma Laboratorios

North America was the largest region in the filgrastim biosimilar markets market in 2023. The Middle East is expected to be the fastest growing region in the global filgrastim biosimilar markets market during the forecast period. The regions covered in the filgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the filgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The filgrastim biosimilar markets consist of sales of Zarxio, Nivestym, and Releuko. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Filgrastim Biosimilars Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on filgrastim biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for filgrastim biosimilars? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The filgrastim biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of covid 19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Type Of Manufacturing: In-House Manufacturing; Contract Manufacturing organization
• 2) By Application: Oncology; Chronic And Autoimmune Diseases; Blood Disorders; Growth Hormone Deficiency; Other Applications
• 3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
• Companies Mentioned: Teva Pharmaceutical Industries Ltd; Novartis International AG; Biocon Limited; Intas Biopharmaceuticals; Dr. Reddy's Laboratories
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Filgrastim Biosimilars Market Characteristics

3. Filgrastim Biosimilars Market Trends And Strategies

4. Filgrastim Biosimilars Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Filgrastim Biosimilars Market Size and Growth

• 5.1. Global Filgrastim Biosimilars Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Filgrastim Biosimilars Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Filgrastim Biosimilars Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Filgrastim Biosimilars Market Segmentation

• 6.1. Global Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• In-House Manufacturing
• Contract Manufacturing Organization
• 6.2. Global Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Oncology
• Chronic And Autoimmune Diseases
• Blood Disorders
• Growth Hormone Deficiency
• Infectious Diseases
• Other Applications
• 6.3. Global Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

7. Filgrastim Biosimilars Market Regional And Country Analysis

• 7.1. Global Filgrastim Biosimilars Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Filgrastim Biosimilars Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Filgrastim Biosimilars Market

• 8.1. Asia-Pacific Filgrastim Biosimilars Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Filgrastim Biosimilars Market

• 9.1. China Filgrastim Biosimilars Market Overview
• 9.2. China Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Filgrastim Biosimilars Market

• 10.1. India Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Filgrastim Biosimilars Market

• 11.1. Japan Filgrastim Biosimilars Market Overview
• 11.2. Japan Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Filgrastim Biosimilars Market

• 12.1. Australia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Filgrastim Biosimilars Market

• 13.1. Indonesia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Filgrastim Biosimilars Market

• 14.1. South Korea Filgrastim Biosimilars Market Overview
• 14.2. South Korea Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Filgrastim Biosimilars Market

• 15.1. Western Europe Filgrastim Biosimilars Market Overview
• 15.2. Western Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Filgrastim Biosimilars Market

• 16.1. UK Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Filgrastim Biosimilars Market

• 17.1. Germany Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Filgrastim Biosimilars Market

• 18.1. France Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Filgrastim Biosimilars Market

• 19.1. Italy Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Filgrastim Biosimilars Market

• 20.1. Spain Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Filgrastim Biosimilars Market

• 21.1. Eastern Europe Filgrastim Biosimilars Market Overview
• 21.2. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Filgrastim Biosimilars Market

• 22.1. Russia Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Filgrastim Biosimilars Market

• 23.1. North America Filgrastim Biosimilars Market Overview
• 23.2. North America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Filgrastim Biosimilars Market

• 24.1. USA Filgrastim Biosimilars Market Overview
• 24.2. USA Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Filgrastim Biosimilars Market

• 25.1. Canada Filgrastim Biosimilars Market Overview
• 25.2. Canada Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Filgrastim Biosimilars Market

• 26.1. South America Filgrastim Biosimilars Market Overview
• 26.2. South America Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Filgrastim Biosimilars Market

• 27.1. Brazil Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Filgrastim Biosimilars Market

• 28.1. Middle East Filgrastim Biosimilars Market Overview
• 28.2. Middle East Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Filgrastim Biosimilars Market

• 29.1. Africa Filgrastim Biosimilars Market Overview
• 29.2. Africa Filgrastim Biosimilars Market, Segmentation By Type Of Manufacturing, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Filgrastim Biosimilars Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Filgrastim Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Filgrastim Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Filgrastim Biosimilars Market Competitive Landscape
• 30.2. Filgrastim Biosimilars Market Company Profiles
  • 30.2.1. Teva Pharmaceutical Industries Ltd
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Novartis International AG
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Biocon Limited
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Intas Biopharmaceuticals
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Dr. Reddy's Laboratories
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Filgrastim Biosimilars Market Other Major And Innovative Companies

• 31.1. Pfizer
• 31.2. Cadila Healthcare Ltd
• 31.3. Abbott Laboratories
• 31.4. Reliance Life Science Pvt. Ltd
• 31.5. Gennova Biopharmaceuticals (Emcure)
• 31.6. Sandoz Pty Ltd
• 31.7. Apotex Pty Ltd
• 31.8. Mylan
• 31.9. Kyowa Kirin Co. Ltd
• 31.10. Lupin Limited
• 31.11. Biocon Biologics
• 31.12. Coherus Biosciences Inc.
• 31.13. North China Pharmaceutical Corporation
• 31.14. Tonghua Dongbaoare
• 31.15. Beijing SL Pharmaceutical

32. Global Filgrastim Biosimilars Market Competitive Benchmarking

33. Global Filgrastim Biosimilars Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Filgrastim Biosimilars Market

35. Filgrastim Biosimilars Market Future Outlook and Potential Analysis

• 35.1 Filgrastim Biosimilars Market In 2028 - Countries Offering Most New Opportunities
• 35.2 Filgrastim Biosimilars Market In 2028 - Segments Offering Most New Opportunities
• 35.3 Filgrastim Biosimilars Market In 2028 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer